Ethical and legal aspects of cancer genetic testing.

abstract：:Cervical cancer is the second most common malignancy in women and the third most common cause of cancer mortality worldwide. While primary and secondary preventions exist, the lack of widespread adoption leaves the treatment of cervical cancer an important oncologic problem. In this article, the management of early an...

journal_title：Seminars in oncology

authors： Barbera L,Thomas G

更新日期：2009-04-01 00:00:00

abstract：:A substantial proportion of patients with squamous cell carcinoma of the head and neck have extensive locoregional disease at presentation. While extensive surgical procedures may completely eradicate local disease with acceptable morbidity for smaller tumors, in patients with stage III and IV disease, high local rela...

journal_title：Seminars in oncology

authors： Eisenberger M,Jacobs M

更新日期：1992-08-01 00:00:00

abstract：:The consistently high mortality rates associated with gastrointestinal cancer result in large part from malignancies that progress undetected to an advanced stage of disease when treatment is usually less effective. In response to this fact, increasing attention has been directed toward developing methods of both prim...

journal_title：Seminars in oncology

authors： Winawer SJ

更新日期：1991-02-01 00:00:00

abstract：:Long-term survival is occasionally observed in patients with neoplastic meningitis (NM) accompanying breast cancer (13% one-year and 6% 2-year survival), melanoma, and lymphoma, but in general the survival of most patients is short and averages only 3 to 4 months. The incidence of NM appears to be increasing, in part ...

journal_title：Seminars in oncology

authors： Jaeckle KA

更新日期：2006-06-01 00:00:00

abstract：:Transitional cell carcinoma of the urothelium is a highly chemosensitive tumor. Combination chemotherapy can provide both palliation and a modest survival advantage in patients with advanced disease. As shown in a recent phase III trial, the new gold standard should be considered gemcitabine/cisplatin, although toxici...

journal_title：Seminars in oncology

authors： Carles J,Nogué M

更新日期：2001-06-01 00:00:00

abstract：:The current study was conducted to determine the risk of adverse outcomes among patients with monoclonal gammopathy of undetermined significance (MGUS) of the IgM class. Two hundred thirteen patients with IgM MGUS were identified in southeastern Minnesota from 1960 to 1994. The primary end point was progression to lym...

journal_title：Seminars in oncology

authors： Kyle RA,Therneau TM,Rajkumar SV,Offord JR,Larson DR,Plevak MF,Melton LJ 3rd

更新日期：2003-04-01 00:00:00

abstract：:Adrenocortical cancer (ACC) is a rare, challenging disease with a broad range of clinical presentations. Often presenting in an advanced stage with a large, locally invasive primary tumor or with Cushing's syndrome, it requires a multidisciplinary approach to treatment. We discuss controversies in the evaluation and m...

journal_title：Seminars in oncology

authors： Balasubramaniam S,Fojo T

更新日期：2010-12-01 00:00:00

abstract：:The epidemiologic studies relevant to the hypothesis that exposure to tamoxifen is associated with risk of cancer of the endometrium and perhaps other organs are described, summarized, and evaluated. One large body of data comes from the randomized trials of tamoxifen as a therapeutic agent against established breast ...

journal_title：Seminars in oncology

authors： MacMahon B

更新日期：1997-02-01 00:00:00

abstract：:A phase II study was conducted to evaluate the efficacy and toxicity of lomustine, cytarabine, mitoxantrone and prednisone (CAMP) chemotherapy in doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphomas (NHL). Among 30 patients, the complete remission rate was 27% (duration: 10, 16, 22, 35,...

journal_title：Seminars in oncology

authors： Ruit JB,Löwenberg B,Hagenbeek A,Verhoef GE,Wielenga JJ,Michiels J,Sizoo W

更新日期：1990-12-01 00:00:00

abstract：:Platinum compounds have long played a role in the treatment of gynecologic cancers. Single-agent cisplatin and carboplatin have shown activity in endometrial cancer, and more recent studies have begun to investigate a variety of new platinum-based combinations. In cervical cancer, chemotherapy is used primarily to tre...

journal_title：Seminars in oncology

authors： Muggia FM

更新日期：2004-12-01 00:00:00

abstract：:Dry mouth (xerostomia) is one of the most common complaints following radiation therapy (RT) for head and neck cancers. Notably, RT causes irreparable damage to salivary glands that increases the risk for severe and long-term oral and pharyngeal disorders. Several strategies in the treatment of head and neck cancers h...

journal_title：Seminars in oncology

authors： Ship JA,Hu K

更新日期：2004-12-01 00:00:00

abstract：:Studies in vitro and in animal models have helped define the mechanism of action of antiestrogens and the differences in the physical properties of the various antiestrogens. Tamoxifen is the most widely studied antiestrogen. A review of 45 separate studies has shown a response rate to tamoxifen in advanced breast can...

journal_title：Seminars in oncology

authors： Lippman ME

更新日期：1983-12-01 00:00:00

abstract：:Solid organ tumors associated with neoangiogenesis, as measured by increased microvessel density (MVD), have poorer prognoses. A similar observation of increased MVD has been made in hematologic malignancies; however, its prognostic significance remains unknown. We investigated changes in MVD in 122 newly diagnosed mu...

journal_title：Seminars in oncology

authors： Munshi NC,Wilson C

更新日期：2001-12-01 00:00:00

abstract：:Cardiovascular toxicity is one of the most feared complications of cancer treatment. Recent advances in oncologic therapies have resulted in improved cancer outcomes but also a new set of cardiovascular adverse effects. Common toxicities include left ventricular dysfunction/heart failure, hypertension, and myocardial ...

journal_title：Seminars in oncology

authors： Davis M,Witteles RM

更新日期：2013-04-01 00:00:00

abstract：:Ten years of interferon (IFN) therapy have followed the approval of this agent by the US Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the many new biotherapeutics. Regardless of this long history, however, we have just touched the surface of understand...

journal_title：Seminars in oncology

authors： Pestka S

更新日期：1997-06-01 00:00:00

abstract：:As continuous ambulatory peritoneal dialysis becomes more popular, the science of catheter selection, insertion, and maintenance becomes increasingly necessary. The proper use of and possible complications associated with several currently used catheters are discussed. The pros and cons of single- and double-cuff cath...

journal_title：Seminars in oncology

authors： Twardowski ZJ

更新日期：1985-09-01 00:00:00

abstract：:Investigators representing all major melanoma research areas present an overview of the most important challenges for the field. Four major research areas are covered plus the training of new investigators. For each area we first describe the present status, its strengths and weaknesses, and then outline specific reco...

journal_title：Seminars in oncology

authors： Herlyn M,Halaban R,Ronai Z,Schuchter L,Berwick M,Pinkel D

更新日期：2007-12-01 00:00:00

abstract：:Interferon-alpha (IFN-alpha) therapy is frequently associated with significant fatigue, which is often the dominant dose-limiting side effect. The fatigue associated with IFN-alpha therapy is usually dose related, worsens with continued therapy, and is associated with significant depression. Although the direct cause ...

journal_title：Seminars in oncology

authors： Dalakas MC,Mock V,Hawkins MJ

更新日期：1998-02-01 00:00:00

abstract：:Letrozole has proven efficacious in a variety of therapeutic scenarios, including that of extended adjuvant therapy following 5 years of tamoxifen treatment in postmenopausal women with estrogen-receptor-positive early breast cancer. The Breast International Group 1-98 trial (BIG 1-98) is the first to study the effica...

journal_title：Seminars in oncology

authors： Forbes JF

更新日期：2006-04-01 00:00:00

abstract：:Cancer clinical trials represent an important option for patients with a diagnosis of cancer and the clinician-investigators involved in their care who seek options for their disease. For all who are impacted by cancer, these studies offer opportunities for greater learning. Conducting these important studies involves...

journal_title：Seminars in oncology

authors： Schiller SJ,Shannon C,Brophy MT,Denicoff AM,Good MJ,Prindiville SA,Huang GD

更新日期：2019-01-01 00:00:00

abstract：:Developments in the treatment of extensive small cell lung cancer have proven effective in palliative management but have not yielded improvements in the cure rate for this disease. Strategies involving dose escalation of chemotherapy, including de novo and late intensification dose escalation and dose escalation with...

journal_title：Seminars in oncology

authors： Comis RL

更新日期：1992-12-01 00:00:00

abstract：:The acute tumor lysis syndrome (ATLS) is characterized by the rapid development of hyperuricemia, hyperkalemia, hyperphosphatemia, and acute renal failure (ARF). Hematologic malignancies are responsible for most cases of ATLS. Control of hyperuricemia and the achievement of a high urine flow are the mainstays of preve...

journal_title：Seminars in oncology

authors： Flombaum CD

更新日期：2000-06-01 00:00:00

abstract：:A phase I/II study was conducted to determine the response rate and the toxicity of escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin with granulocyte colony-stimulating factor support in patients with untreated advanced head and neck carcinoma. Twenty-eight patients wi...

journal_title：Seminars in oncology

authors： Hitt R,Paz-Ares L,Hidalgo M,Colomer R,Brandariz A,Peña M,Alvarez-Vicent J,Hornedo J,Cortés-Funes H

更新日期：1997-12-01 00:00:00

abstract：:The liver is the most common site of metastatic colorectal cancer (CRC) and the status of this organ is an important determinant of overall survival in patients with advanced disease. Complete resection of hepatic CRC metastases can provide a long-term cure for some patients, but the majority of liver metastases are n...

journal_title：Seminars in oncology

authors： Ruan DT,Warren RS

更新日期：2005-02-01 00:00:00

abstract：:Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin production in pathologic states such as inflammatory processes and cancer. The enzyme is often overexpressed in premalignant lesions and various cancers, including cancer of the lung. Inhibition of this enzyme with selective COX-2 inhibitors was found to ...

journal_title：Seminars in oncology

authors： Komaki R,Liao Z,Milas L

更新日期：2004-02-01 00:00:00

abstract：:Significant achievements in the basic sciences have led to a greater knowledge of the underlying signaling pathways in renal cell cancer (RCC), including the mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt pathway). The mTOR pathway has a central role in the regulation of cell growth and in...

journal_title：Seminars in oncology

authors： Pantuck AJ,Thomas G,Belldegrun AS,Figlin RA

更新日期：2006-10-01 00:00:00

abstract：:In vitro uptake and retention of 3H-cytosine arabinoside (ara-C) was studied in 68 acute myelogenous leukemia (AML) patients (ten were studied twice) treated with a regimen containing conventional (54 patients) or high doses (24) of ara-C. Drug uptake and retention after four hours were measured following 30 minutes e...

journal_title：Seminars in oncology

authors： Zittoun R,Marie JP,Delanian S,Suberville AM,Thevenin D

更新日期：1987-06-01 00:00:00

abstract：:Distant metastasis is the major cause for therapeutic failures in Clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease....

journal_title：Seminars in oncology

authors： Gilboa E

更新日期：1996-02-01 00:00:00

abstract：:Vinorelbine, a vinca alkaloid, was the first drug in over 20 years to be approved by the Food and Drug Administration for treatment of advanced non-small cell lung cancer (NSCLC). The drug's nonhematologic toxicities are usually mild; its dose-limiting toxicity is neutropenia. Vinorelbine has been studied in many phas...

journal_title：Seminars in oncology

authors： Wozniak AJ

更新日期：1999-10-01 00:00:00

abstract：:Eighteen percent of incident malignancies in the United States are a second (or subsequent) cancer. Second primary neoplasms (SPNs), particularly solid tumors, are a major cause of mortality and serious morbidity among cancer survivors successfully cured of their first cancer. Multiple etiologies may lead to a cancer ...

journal_title：Seminars in oncology

authors： Oeffinger KC,Baxi SS,Novetsky Friedman D,Moskowitz CS

更新日期：2013-12-01 00:00:00